Capecitabine and Warfarin Interaction: A Case Report With Review of Literature and Management Options

被引：1

作者：

Althiab, Khalefa ^{[1
,2
,3
,4
]}

Aljohani, Manal ^{[1
,2
,3
,4
]}

Alraddadi, Sultan ^{[1
,2
,3
,4
]}

Algarni, Mohammed ^{[2
,3
,4
,5
]}

机构：

[1] King Abdul Aziz Med City, Dept Pharm Serv, Riyadh, Saudi Arabia

[2] Minist Natl Guard Hlth Affair, Riyadh, Saudi Arabia

[3] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia

[4] King Saud bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia

[5] King Abdul Aziz Med City, Adult Oncol Dept, Riyadh, Saudi Arabia

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 8卷

关键词：

warfarin; capecitabine; drug interaction; international normalized ratio (INR); case report;

D O I：

10.3389/fcvm.2021.707361

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Capecitabine is an orally active prodrug of 5-fluorouracil with improved safety and efficacy that is extensively used as an antineoplastic agent. It is converted to 5-Fluorouracil in the liver and tumor tissues. In vitro assays did not reveal any significant potential for interaction between capecitabine and its metabolites with warfarin. However, several reports provided clinical evidence of such interaction resulting in an elevated international normalized ratio (INR) and bleeding. Here, we report another case of capecitabine and warfarin concurrent administration that resulted in sub- or supra- therapeutic INR without any bleeding episode or venous-thromboembolic event through the follow-up period. Moreover, a review of available management options is also presented in this paper.

引用

页数：7

共 22 条

[1] Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer [J].

Agnelli, Giancarlo ;

Becattini, Cecilia ;

Meyer, Guy ;

Munoz, Andres ;

Huisman, Menno, V ;

Connors, Jean M. ;

Cohen, Alexander ;

Bauersachs, Rupert ;

Brenner, Benjamin ;

Torbicki, Adam ;

Sueiro, Maria R. ;

Lambert, Catherine ;

Gussoni, Gualberto ;

Campanini, Mauro ;

Fontanella, Andrea ;

Vescovo, Giorgio ;

Verso, Melina .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (17) :1599-1607

[2] Capecitabine-induced potentiation of warfarin [J].

Buyck, HCE ;

Buckley, N ;

Leslie, MD ;

Plowman, PN .

CLINICAL ONCOLOGY, 2003, 15 (05) :297-297

[3] Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer [J].

Camidge, R ;

Reigner, B ;

Cassidy, J ;

Grange, S ;

Abt, M ;

Weidekamm, E ;

Jodrell, D .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4719-4725

[4]

Copur M S, 2001, Clin Colorectal Cancer, V1, P182, DOI 10.3816/CCC.2001.n.019

[5] Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy [J].

Di Nisio, Marcello ;

Porreca, Ettore ;

Candeloro, Matteo ;

De Tursi, Michele ;

Russi, Ilaria ;

Rutjes, Anne W. S. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (12)

[6] Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report [J].

Giunta, Giovanni .

CASE REPORTS IN MEDICINE, 2010, 2010

[7] Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect [J].

Grandoni, Francesco ;

Alberio, Lorenzo .

CANCERS, 2019, 11 (01)

[8]

Hoffman-LaRoche Inc, 2015, WARNING XELODA WARFA

[9] Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease [J].

Dieter Horstkotte ;

Cornelia Piper ;

Marcus Wiemer .

Journal of Thrombosis and Thrombolysis, 1998, 5 (Suppl 1) :19-24

[10]

Ikenishi Masayuki, 2015, Gan To Kagaku Ryoho, V42, P833

← 1 2 3 →